Oct 20, 2026 08:12AM
Oct 20, 2026 08:12AM
Oct 16, 2026 09:20AM
Oct 16, 2026 09:20AM
Oct 7, 2026 08:45AM
Sep 29, 2026 08:45AM
Sep 29, 2026 08:45AM Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout
Sep 28, 2026 07:01AM
Sep 28, 2026 07:00AM
Sep 25, 2026 01:05PM
Sep 25, 2026 01:05PM
Sep 23, 2026 08:25AM
Sep 23, 2026 08:25AM
Sep 14, 2026 08:35AM Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings
Sep 11, 2026 08:30AM
Aug 27, 2026 09:01AM
Aug 14, 2026 08:30AM
Jul 31, 2026 10:12AM
Jul 31, 2026 10:12AM
Jul 31, 2026 08:10AM
Jul 31, 2026 08:10AM Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients
Jul 6, 2026 08:33AM
Jul 6, 2026 08:33AM
Jul 6, 2026 08:33AM
Jun 30, 2026 08:30AM
Jun 30, 2026 08:30AM
Jun 5, 2026 08:29AM
Jun 5, 2026 08:29AM Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML
Jun 4, 2026 08:31AM
May 29, 2026 08:21AM
May 21, 2026 05:02PM
May 21, 2026 05:02PM
May 15, 2026 08:30AM
May 13, 2026 08:03AM
May 13, 2026 08:00AM Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks
May 12, 2026 09:30AM
May 12, 2026 09:30AM
May 12, 2026 09:30AM
May 8, 2026 08:45AM
May 8, 2026 08:45AM
Apr 23, 2026 08:27AM
Apr 23, 2026 08:25AM Moleculin’s Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026
Apr 21, 2026 08:36AM
Apr 7, 2026 12:52PM
Apr 7, 2026 08:42AM
Apr 7, 2026 08:36AM
Apr 7, 2026 08:36AM
Mar 23, 2026 08:33AM
Mar 23, 2026 08:31AM Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout
Mar 23, 2026 08:31AM

335,393 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All